U/S Core Biopsy for solid organs (DC) at Dr. Essa Lab

U/S Core Biopsy for solid organs (DC) at Dr. Essa Lab

An ultrasound-guided core needle biopsy is a highly precise, minimally invasive diagnostic procedure used to obtain high-quality tissue samples from solid organs within the body. Unlike a fine-needle aspiration (FNA), which only collects individual cells, a core biopsy utilizes a specialized hollow needle to extract a small, intact cylinder of tissue (a “core”). This preserved tissue architecture is critical for histopathological analysis, allowing pathologists to determine the exact nature of a lesion, differentiate between benign and malignant conditions, and perform advanced molecular testing or immunohistochemistry.

At Dr. Essa Lab, this procedure is performed under real-time ultrasound guidance. High-frequency sound waves are transmitted through a transducer to create live, detailed images of the target organ and surrounding anatomical structures. This allows the interventional radiologist to visualize the precise path of the biopsy needle, avoiding major blood vessels, nerves, and adjacent organs, thereby maximizing diagnostic yield while minimizing patient risk.

The clinical importance of this procedure cannot be overstated. It serves as a definitive diagnostic tool for solid organs such as the liver, kidneys, breast, thyroid, lymph nodes, and soft tissue masses. By providing a definitive tissue diagnosis, the U/S Core Biopsy for solid organs (DC) at Dr. Essa Lab guides oncologists, surgeons, and internists in formulating highly personalized, evidence-based treatment plans, preventing unnecessary surgical interventions and ensuring timely therapeutic management.

Clinical Procedure: What to Expect

Patient Preparation

To ensure patient safety and the highest diagnostic accuracy, specific preparation guidelines must be followed before undergoing a U/S Core Biopsy for solid organs (DC) at Dr. Essa Lab:

• Coagulation Profile: Patients must undergo blood tests, including Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), and International Normalized Ratio (INR), within a week prior to the procedure to assess blood clotting function and minimize bleeding risks.
• Medication Adjustment: Patients must inform their physician and the radiologist about all medications they are currently taking. Blood thinners, anticoagulants, and antiplatelet agents (such as aspirin, warfarin, clopidogrel, or enoxaparin) must typically be discontinued for 3 to 7 days before the biopsy, under medical supervision.
• Fasting Requirements: For abdominal organs (such as the liver, kidney, or pancreas), patients are generally required to fast (no food or drink) for 6 to 8 hours prior to the procedure to reduce bowel gas and optimize ultrasound visualization. For superficial organs (like the breast or thyroid), fasting is usually not required.
• Medical History and Allergies: Patients must disclose any history of allergies, particularly to local anesthetics (like lidocaine), latex, or sterile prep solutions, as well as any underlying medical conditions like severe hypertension or chronic kidney disease.
• Arranging Transportation: Because local anesthesia and mild sedation (if requested) are used, patients should arrange for a family member or friend to drive them home after the procedure.

During the Procedure

The U/S Core Biopsy for solid organs (DC) is performed in a dedicated, sterile interventional suite at Dr. Essa Lab:

• Patient Positioning: The patient is positioned comfortably on an examination table. The exact position depends on the target organ; for example, a liver biopsy requires lying supine or slightly tilted to the left, while a kidney biopsy is typically performed in a prone position (lying on the stomach).
• Ultrasound Localization: The radiologist uses an ultrasound probe to locate the target lesion, determine its depth, and plan the safest trajectory for the biopsy needle.
• Sterile Preparation and Local Anesthesia: The skin over the biopsy site is thoroughly cleansed with an antiseptic solution and draped with sterile towels. A local anesthetic (typically 1% or 2% lidocaine) is injected into the skin and underlying tissues down to the organ capsule to ensure the procedure is virtually painless.
• Needle Insertion and Tissue Sampling: A small skin nick (1-2 mm) is made to facilitate needle entry. Under continuous, real-time ultrasound visualization, the radiologist guides the core biopsy needle to the edge of the lesion. The biopsy gun is then activated, making a rapid clicking sound as it quickly advances and retracts to capture a tissue core. This process may be repeated 2 to 4 times to obtain sufficient tissue samples.
• Post-Procedure Care: Once adequate samples are obtained, the needle is removed, and firm, direct pressure is applied to the site for 10 to 15 minutes to prevent bleeding. A sterile adhesive bandage or compression dressing is then applied. No sutures are required.
• Observation Period: Patients are monitored in a recovery area for 2 to 4 hours, where their vital signs (blood pressure, heart rate) are checked regularly, and the biopsy site is monitored for any signs of immediate complications.

When is a U/S Core Biopsy for solid organs (DC) Performed?

Evaluation of Suspected Hepatic Masses

Physicians frequently request a U/S Core Biopsy for solid organs (DC) when imaging studies (such as an ultrasound, CT, or MRI) reveal an indeterminate mass, nodule, or diffuse abnormality in the liver. Patients presenting with symptoms like unexplained jaundice, right upper quadrant abdominal pain, unexplained weight loss, or persistent elevations in liver enzymes may require this procedure. The biopsy helps differentiate between primary liver cancers (like hepatocellular carcinoma), metastatic lesions originating from other organs, and benign conditions such as focal nodular hyperplasia, hepatic adenomas, or severe steatohepatitis, allowing for accurate staging and treatment planning.

Investigation of Renal Parenchymal Disease or Masses

A core biopsy of the kidney is indicated when a patient presents with an unexplained renal mass, persistent hematuria (blood in the urine), severe proteinuria (excess protein in the urine), or rapidly progressive renal failure. Under ultrasound guidance, the biopsy needle targets either a focal renal mass to rule out renal cell carcinoma or the renal cortex to diagnose complex parenchymal diseases, such as glomerulonephritis, lupus nephritis, or interstitial nephritis. This precise tissue diagnosis is crucial for guiding immunosuppressive therapy or planning surgical resection.

Characterization of Breast Nodules and Masses

When a screening mammogram, breast ultrasound, or physical examination reveals a suspicious breast lump (classified as BI-RADS 4 or 5), a U/S Core Biopsy is the gold standard for diagnostic confirmation. Patients presenting with a palpable, firm breast mass, skin dimpling, or nipple retraction undergo this procedure to distinguish benign fibroadenomas or fibrocystic changes from invasive ductal or lobular carcinoma. The retrieved core samples allow pathologists to evaluate hormone receptor status (ER, PR, HER2), which directly dictates the oncological treatment pathway.

Assessment of Unexplained Lymphadenopathy

Persistent, enlarged lymph nodes in the neck, axilla, or groin that do not resolve with conservative treatment require diagnostic evaluation. Patients presenting with systemic symptoms such as chronic fever, night sweats, and unexplained weight loss (B-symptoms) are primary candidates for a U/S Core Biopsy. The procedure assists in distinguishing reactive lymph node hyperplasia due to infections from malignant conditions like Hodgkin lymphoma, non-Hodgkin lymphoma, or metastatic disease from a primary solid tumor elsewhere in the body.

Diagnostic Workup of Splenic or Pancreatic Lesions

Focal lesions within the spleen or pancreas are challenging to diagnose using non-invasive imaging alone. A physician may request a U/S Core Biopsy for patients presenting with deep abdominal pain, early satiety, unexplained weight loss, or progressive splenomegaly. The biopsy provides definitive histopathological evidence to differentiate pancreatic adenocarcinoma or neuroendocrine tumors from chronic pancreatitis, and to identify splenic lymphoma, granulomatous infections (such as tuberculosis), or benign vascular lesions, preventing unnecessary and highly invasive surgeries.

What Does a U/S Core Biopsy for solid organs (DC) Detect?

A U/S Core Biopsy for solid organs (DC) at Dr. Essa Lab is capable of detecting a wide range of benign, infectious, inflammatory, and malignant conditions across various organ systems. Key findings include:

• Hepatocellular Carcinoma (HCC): Primary malignant tumor of the liver parenchymal cells.
• Metastatic Carcinoma: Secondary tumors in solid organs (e.g., liver, lymph nodes) originating from primary sites like the colon, lungs, or breast.
• Hepatic Steatohepatitis: Inflammation and fat accumulation in liver tissue, indicating NASH/MASH.
• Liver Cirrhosis: Advanced fibrosis and regenerative nodules indicating chronic liver damage.
• Renal Cell Carcinoma (RCC): The most common type of primary kidney cancer.
• Glomerulonephritis: Various forms of inflammatory kidney diseases affecting the glomeruli.
• Lupus Nephritis: Autoimmune-mediated kidney inflammation in patients with systemic lupus erythematosus.
• Invasive Ductal Carcinoma (IDC): The most common form of breast cancer.
• Breast Fibroadenoma: A common, benign glandular and fibrous breast tumor.
• Ductal Carcinoma In Situ (DCIS): Non-invasive breast cancer confined to the milk ducts.
• Hodgkin and Non-Hodgkin Lymphoma: Malignancies of the lymphatic system detected via lymph node biopsy.
• Reactive Lymph Node Hyperplasia: Benign enlargement of lymph nodes in response to infection or inflammation.
• Tuberculous Lymphadenitis: Chronic granulomatous infection of lymph nodes caused by Mycobacterium tuberculosis.
• Pancreatic Adenocarcinoma: Highly aggressive primary malignancy of the pancreatic ductal cells.
• Pancreatic Neuroendocrine Tumors (pNETs): Neoplasms arising from the endocrine cells of the pancreas.
• Autoimmune Pancreatitis: A form of chronic pancreatitis characterized by autoimmune involvement.
• Splenic Lymphoma: Primary or secondary involvement of the spleen by lymphatic malignancy.
• Granulomatous Splenitis: Inflammatory changes in the spleen due to sarcoidosis or fungal infections.
• Thyroid Papillary Carcinoma: The most common form of well-differentiated thyroid cancer.
• Benign Thyroid Colloid Nodule: Non-cancerous, fluid-filled or gelatinous enlargement of the thyroid gland.
• Amyloidosis: Abnormal protein deposits in solid organs like the kidney or liver.
• Focal Nodular Hyperplasia (FNH): A benign, tumor-like vascular malformation of the liver.
• Hepatic Adenoma: A benign liver tumor associated with oral contraceptive use.
• Acute or Chronic Interstitial Nephritis: Inflammation of the space between kidney tubules, often drug-induced.
• Soft Tissue Sarcoma: Malignant tumors arising from extraskeletal connective tissues.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that waiting for biopsy results can be an anxious time for patients and their families. The tissue cores obtained during the U/S Core Biopsy for solid organs (DC) are immediately placed in a preservative solution (formalin) and transported to our state-of-the-art histopathology laboratory. Here, the samples undergo meticulous processing, sectioning, and staining.

The preliminary histopathology report is typically compiled within 3 to 5 working days. In complex cases requiring specialized immunohistochemistry (IHC) stains or molecular profiling to determine exact tumor subtypes, the final comprehensive report may take 5 to 7 working days.

Dr. Essa Lab offers seamless and convenient access to diagnostic reports. Patients can easily download their verified reports online through the official Dr. Essa Lab web portal or mobile application using the unique patient ID and password provided on their receipt. Physical copies of the reports can also be collected from the primary diagnostic center in Karachi or any of our numerous convenient collection branches located across the city.

U/S Core Biopsy for solid organs (DC) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Liver Parenchyma	Normal hepatocyte architecture, no fibrosis, no cellular atypia, no inflammation.	Hepatocellular carcinoma, metastatic disease, cirrhosis, steatohepatitis, granulomas.
Kidney Tissue	Intact glomeruli, tubules, and interstitium; no immune complex deposition.	Glomerulonephritis, renal cell carcinoma, lupus nephritis, amyloidosis, interstitial nephritis.
Breast Tissue	Normal lobular and ductal structures, fibroadipose tissue without atypia.	Invasive ductal carcinoma, fibroadenoma, ductal carcinoma in situ (DCIS), atypical hyperplasia.
Lymph Nodes	Preserved nodal architecture, normal germinal centers, no atypical cells.	Lymphoma (Hodgkin/Non-Hodgkin), metastatic carcinoma, tuberculous lymphadenitis, reactive hyperplasia.
Pancreatic Tissue	Normal acinar and ductal cells, intact islets of Langerhans, no atypia.	Pancreatic adenocarcinoma, neuroendocrine tumors, chronic pancreatitis, autoimmune pancreatitis.
Splenic Tissue	Normal red and white pulp distribution, no abnormal cellular infiltration.	Splenic lymphoma, granulomatous splenitis, extramedullary hematopoiesis, hemangioma.
Thyroid Nodules	Normal follicular cells filled with colloid, no nuclear features of malignancy.	Papillary thyroid carcinoma, follicular neoplasm, medullary carcinoma, Hashimoto’s thyroiditis.
Soft Tissue Masses	Normal skeletal muscle, adipose, or fibrous tissue without cellular atypia.	Liposarcoma, leiomyosarcoma, fibromatosis, benign lipoma, schwannoma.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for U/S Core Biopsy for solid organs (DC)?

• Experienced Healthcare Professionals: Our interventional radiology and pathology teams consist of highly trained, board-certified consultants with extensive experience in performing and interpreting image-guided biopsies.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the entire biopsy procedure and recovery period.
• Quality Diagnostic Services: Dr. Essa Lab is committed to maintaining the highest standards of diagnostic accuracy, utilizing rigorous quality control protocols.
• Professional Reporting: Detailed, comprehensive histopathological reports are generated by senior pathologists, ensuring precise and actionable diagnostic information.
• Modern Diagnostic Approach: We integrate advanced real-time ultrasound imaging with state-of-the-art laboratory processing to deliver superior clinical outcomes.
• Comfortable Environment: Our dedicated interventional suites and recovery rooms are designed to provide a calm, sterile, and reassuring environment for patients.
• Convenient Location: With a primary diagnostic hub in Karachi and an extensive network of collection centers, accessing our services is highly convenient.
• Commitment to Accurate Diagnosis: Since 1987, Dr. Essa Lab has built a legacy of trust, providing reliable and timely diagnostic insights to support effective patient care.